CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Canagliflozin +1 moredrug
Likely dose
Canagliflozin 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02360774
NCT02360774Phase 4Completed
CompareCT.gov

Mechanisms of Weight Loss With SGLT2 Inhibition

Beth Israel Deaconess Medical Center·interventional·Posted Feb 11, 2015·Updated Aug 3, 2018

In Brief

A Phase 4 clinical trial evaluating Canagliflozin and Placebo for Type 2 Diabetes and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or obese. Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than absorb, glucose. Canagliflozin is also often associated with weight loss. The study population will generally be type 2 diabetics, ages 18-75 years old, who are overweight or obese.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Overweight, Obesity
CountriesUnited States
CollaboratorsJanssen Scientific Affairs, LLC

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 11, 2015
Enrollment StartFeb 1, 2015
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.4 years ago

Interventions

Canagliflozindrug

Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.

Placebodrug

Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.